Treatment with trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2), has improved the prognosis for patients with HER2-positive breast cancer (Moja et al., 2012) and gastric cancer (Gong et al., 2016). The gene discussed is ERBB2; the disease is breast cancer.